Management of irritable bowel syndrome

被引：17

作者：

Gunn, MC ^{[1
]}

Cavin, AA ^{[1
]}

Mansfield, JC ^{[1
]}

机构：

[1] Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England

来源：

POSTGRADUATE MEDICAL JOURNAL | 2003年 / 79卷 / 929期

关键词：

FUNCTIONAL GASTROINTESTINAL DISORDERS; RISK-FACTORS; SYMPTOMS; DIAGNOSIS; PREVALENCE; COMMUNITY; TRANSIT; CONSTIPATION; DYSFUNCTION; DISTENSION;

D O I：

10.1136/pmj.79.929.154

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

The diagnosis of irritable bowel syndrome (IBS) is made on clinical grounds with appropriate limited investigations to exclude organic disease. IBS is common and may have a significant impact on a patient's quality of life. Psychological symptoms are common. IBS may benefit from pharmacological and non-pharmacological management. Specific measures should be directed towards the dominant symptoms of constipation or diarrhoea. Several new drugs are currently under evaluation and may prove valuable for subgroups of patients with IBS. Successful management requires a combination of reassurance and explanation about the natural history of the condition.

引用

页码：154 / 158

页数：5

共 56 条

[1]

PREDOMINANT SYMPTOMS IN IRRITABLE-BOWEL-SYNDROME CORRELATE WITH SPECIFIC AUTONOMIC NERVOUS-SYSTEM ABNORMALITIES [J].

AGGARWAL, A ;

CUTTS, TF ;

ABELL, TL ;

CARDOSO, S ;

FAMILONI, B ;

BREMER, J ;

KARAS, J .

GASTROENTEROLOGY, 1994, 106 (04) :945-950

[2]

AUTONOMIC DYSFUNCTION IN GASTROINTESTINAL MOTILITY DISORDERS [J].

BHARUCHA, AE ;

CAMILLERI, M ;

LOW, PA ;

ZINSMEISTER, AR .

GUT, 1993, 34 (03) :397-401

[3]

Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder [J].

Bouras, EP ;

Camilleri, M ;

Burton, DD ;

Thomforde, G ;

McKinzie, S ;

Zinsmeister, AR .

GASTROENTEROLOGY, 2001, 120 (02) :354-360

[4]

Management of the irritable bowel syndrome [J].

Camilleri, M .

GASTROENTEROLOGY, 2001, 120 (03) :652-668

[5]

Economic burden of irritable bowel syndrome - Proposed strategies to control expenditures [J].

Camilleri, M ;

Williams, DE .

PHARMACOECONOMICS, 2000, 17 (04) :331-338

[6]

Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome [J].

Camilleri, M ;

Heading, RC ;

Thompson, WG .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (08) :1407-1430

[7]

WHAT IS THE BENEFIT OF COARSE WHEAT BRAN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME [J].

CANN, PA ;

READ, NW ;

HOLDSWORTH, CD .

GUT, 1984, 25 (02) :168-173

[8]

PHYSICAL SYMPTOM SEVERITY, PSYCHOLOGICAL AND SOCIAL DYSFUNCTION IN A SERIES OF OUTPATIENTS WITH IRRITABLE-BOWEL-SYNDROME [J].

CORNEY, RH ;

STANTON, R .

JOURNAL OF PSYCHOSOMATIC RESEARCH, 1990, 34 (05) :483-491

[9]

Irritable bowel syndrome - New agents targeting serotonin receptor subtypes [J].

De Ponti, F ;

Tonini, M .

DRUGS, 2001, 61 (03) :317-332

[10]

Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects [J].

Degen, L ;

Matzinger, D ;

Merz, M ;

Appel-Dingemanse, S ;

Osborne, S ;

Lüchinger, S ;

Bertold, R ;

Maecke, H ;

Beglinger, C .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (11) :1745-1751

← 1 2 3 4 5 6 →